Monoclonal antibodies targeting IL-5 (Mepolizumab) and IL-5 receptor α (Benralizumab) were recently approved to treat asthma; however, initial clinical studies on Mepolizumab have yielded conflicting findings. This evidence concerns the gene IL5 and asthma.